ARQTArcutis BiotherapeuticsARQT info
$10.58info4.12%24h
Global rank7870
Market cap$998.47M
Change 7d3.41%
YTD Performance233.72%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Arcutis Biotherapeutics (ARQT) Stock Overview

    Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

    ARQT Stock Information

    Symbol
    ARQT
    Address
    3027 Townsgate RoadWestlake Village, CA 91361United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.arcutis.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    805 418 5006

    Arcutis Biotherapeutics (ARQT) Price Chart

    -
    Value:-

    Arcutis Biotherapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $10.58
    N/A
    Market Cap
    $998.47M
    N/A
    Shares Outstanding
    94.38M
    N/A
    Employees
    268.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org